Risks and prevention of infections
Multiple transfusions of a pooled plasma product such as Factor VIII poses a high risk of acquiring infections:
- approximately 60 % of the haemophiliac population were exposed to HIV - 1 before this risk was recognised
- there is evidence of prior hepatitis B infection in many older haemophiliacs
- approximately 75% of haemophiliacs have antibodies to hepatitis C virus - 50% of whom will develop evidence of chronic liver disease
Steps taken to reduce the risk of infection include:
- vaccination against hepatitis B virus in all newly diagnosed haemophiliacs
- screening of plasma donors for hepatitis and HIV virus infection
- routine sterilisation of all forms of Factor VIII concentrates except for cryoprecipitate - by heat or solvent / detergent
- viral inactivation methods - for hepatitis virus
- cryoprecipitate carriers a lower risk of infection than other forms of Factor VIII because fewer donors are involved - but methods for routine treatment of this blood component are not yet available
- use of non-blood products such as DDAVP (a synthetic vasopressin) and/or tranexamic acid (anti-fibrinolytic) may preclude need for blood products - suitable only for mild or moderately affected haemophiliacs
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.